Diabetic Foot Ulcers - Pipeline Review, H2 2015 Diabetic Foot Ulcers - Pipeline Review, H2 2015 market research report is the latest addition to RnRMarketResearch.com and its collection of therapeutics business intelligence reports aimed to help take better decisions. This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2, 2015 Pipeline Review of “Diabetic Foot Ulcers� addition with 49 market data tables and 15 figures, spread across 149 pages is http://www.rnrmarketresearch.com/diabetic-foot-ulcers-pipeline-review-h2-2015market-report.html . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Discussed/Mentioned in this Research: Adocia, Aprogen, Inc., Bayer AG, CardioVascular BioTherapeutics, Inc., Celgene Corporation, CoDa Therapeutics, Inc., CytoTools AG, Dipexium Pharmaceuticals LLC, EyeGene, Inc., FirstString Research, Inc., GlaxoSmithKline Plc, Human Stem Cells Institute, Innovaxis, Izun Pharmaceuticals Corporation, Karyopharm Therapeutics, Inc., Lytix Biopharma AS, MediaPharma s.r.l., MediWound Ltd., NovaLead Pharma Pvt. Ltd., Oneness Biotech Co., Ltd., Osiris Therapeutics, Inc., Plurogen Therapeutics, Inc., Sanofi,